CTLA4 and colon carcinoma: In colon carcinoma mice treated with anti-CTLA-4 antibodies, increased butyrate and propionate concentrations in the bloodstream led to resistance, increased Treg proportion, and reduced effectiveness of anti-CTLA-4 therapy [18].